Skip Navigation LinksHome > September 2009 - Volume 17 - Issue 5 > Mortality, Hospital Stay, and Costs Associated With Candidem...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31819fe424
Original Articles

Mortality, Hospital Stay, and Costs Associated With Candidemia After Major Esophagus, Stomach, and Bowel Procedures in US Hospitals

Wood, Craig MD*; Rajagopalan, Srini PhD†; Shivaprakash, Malathi MS*; Chandwani, Sheenu MPH*‡; Turpin, Robin S. PhD*§∥

Collapse Box

Abstract

Premier's Perspective hospital-based database was used to assess mortality, length of stay, and cost for major esophagus, stomach, and bowel procedures in patients with and without candidemia (International Classification of Diseases, Ninth Revision, Clinical Modification, code 112.5, disseminated candidiasis). Candidemia was associated with a 63.8% higher extreme risk of mortality, 37.1% greater in-hospital mortality, 61.2% longer mean length of stay, and 55.4% higher total costs. Antifungal drugs represented 4.0% and 2.4% of the total costs for patients with and without candidemia, respectively. General linear model analysis indicated that candidemia was associated with a significant increase of $15,727 in total costs (t = 5.87; P < 0.0001); antifungal drugs represent a small percentage of these costs.

© 2009 Lippincott Williams & Wilkins, Inc.